| 词条 | Essential thrombocythemia |
| 释义 |
| name = Essential thrombocythemia | synonyms = Essential thrombocythaemia, essential thrombocytosis, primary thrombocytosis | image = Essential Thrombocythaemia.jpg | caption = | pronounce = | field = | symptoms = | complications = | onset = | duration = | types = | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = | frequency = | deaths = }}Essential thrombocythemia (ET) is a rare chronic blood condition characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.[1] It may, albeit rarely, develop into acute myeloid leukemia or myelofibrosis.[1] It is one of four myeloproliferative neoplasms (blood disorders that occur when the body makes too many white or red blood cells, or platelets).[1] Signs and symptomsMost people with essential thrombocythemia are without symptoms at the time of diagnosis, which is usually made after noting an elevated platelet level on a routine complete blood count (CBC).[2] The most common symptoms are bleeding (due to dysfunctional platelets), blood clots (e.g., deep vein thrombosis or pulmonary embolism), headache, nausea, vomiting, abdominal pain, visual disturbances, dizziness, fainting, and numbness in the extremities; the most common signs are increased white blood cell count, reduced red blood cell count, and an enlarged spleen.[2][3][4] CauseIn ET, megakaryocytes are more sensitive to growth factors.{{citation needed|date=November 2017}} Platelets derived from the abnormal megakaryocytes are activated, which, along with the elevated platelet count, contributes to the likelihood of forming blood clots.[5] The increased possibility of bleeding when the platelet count is over 1 million is due to von Willebrand factor (vWF) sequestration by the increased mass of platelets, leaving insufficient vWF for platelet adhesion.[5] A mutation in the JAK2 kinase (V617F) is present in 40–50% of cases and is diagnostic if present.[1][5] JAK2 is a member of the Janus kinase family.[1][5] In 2013, two groups detected calreticulin mutations in a majority of JAK2-negative/MPL-negative patients with essential thrombocythemia and primary myelofibrosis, which makes CALR mutations the second most common in myeloproliferative neoplasms. All mutations (insertions or deletions) affected the last exon, generating a reading frame shift of the resulting protein, that creates a novel terminal peptide and causes a loss of endoplasmic reticulum KDEL retention signal.[6][7] DiagnosisThe following revised diagnostic criteria for essential thrombocythaemia were proposed in 2005.[8] The diagnosis requires the presence of both A criteria together with B3 to B6, or of criterion A1 together with B1 to B6.[17] The criteria are as follows:[9]
TreatmentIndicationsNot all those affected will require treatment at presentation.[10][11][12] People are usually split up into low and high risk for bleeding/blood clotting groups (based on their age, their medical history, their blood counts and their lifestyles), low risk individuals are usually treated with aspirin, whereas those at high risk are given hydroxycarbamide and/or other treatments that reduce platelet count (such as interferon-α and anagrelide).[1][10][11][12] AgentsHydroxycarbamide, interferon-α and anagrelide can lower the platelet count. Low-dose aspirin is used to reduce the risk of blood clot formation unless the platelet count is very high, where there is a risk of bleeding from the disease, and hence this measure would be counter-productive as aspirin-use increases the risk of bleeding.[1][10][11][12]The PT1 study compared hydroxyurea plus aspirin to anagrelide plus aspirin as initial therapy for ET. Hydroxyurea treated patients had a lower incidence of arterial thrombosis, lower incidence of severe bleeding and lower incidence of transformation to myelofibrosis, but the risk of venous thrombosis was higher with hydroxycarbamide than with anagrelide. It is unknown whether the results are applicable to all ET patients.[1][10][11][12] In people with symptomatic ET and extremely high platelet counts (exceeding 1 million), plateletpheresis can be used to remove platelets from the blood to reduce the risk of thrombosis. PrognosisEssential thrombocythemia is sometimes described as a slowly progressive disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic events.[10] However, well-documented medical regimens can reduce and control the number of platelets, which reduces the risk of these thrombotic or hemorrhagic events. The lifespan of a well controlled ET person is well within the expected range for a person of similar age but without ET.[10] ET is the myeloproliferative neoplasm least likely to progress to acute myeloid leukemia. EpidemiologyThe incidence of ET is 0.6-2.5/100,000 per year, the median age at onset is 65–70 years and it is more frequent in females than in males.[13] The incidence in children is 0.09/100,000 per year.[13] PregnancyHydroxycarbamide and anagrelide are contraindicated during pregnancy and nursing.[38] Essential thrombocythemia can be linked with a three-fold increase in risk of miscarriage.[13] Throughout pregnancy, close monitoring of the mother and fetus is recommended.[38] Low-dose low molecular weight heparin (e.g. enoxaparin) may be used.[38] For life-threatening complications, the platelet count can be reduced rapidly using plateletpheresis, a procedure that removes platelets from the blood and returns the remainder to the patient.[14]References1. ^1 2 3 4 5 6 7 {{cite journal |last1=Beer |first1=PA |last2=Green |first2=AR |title=Pathogenesis and management of essential thrombocythemia |journal=Hematology / The Education Program of the American Society of Hematology. American Society of Hematology. Education Program |volume=2009 |date=2009 |pages=621–8 |doi=10.1182/asheducation-2009.1.621 |pmid=20008247 }} 2. ^1 {{cite journal |last1=Fu |first1=R |last2=Zhang |first2=L |last3=Yang |first3=R |title=Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment |journal=British Journal of Haematology |date=November 2013 |volume=163 |issue=3 |pages=295–302 |doi=10.1111/bjh.12530 |pmid=24032343}} 3. ^{{cite journal |last1=Frewin |first1=R |last2=Dowson |first2=A |title=Headache in essential thrombocythaemia.|journal=International Journal of Clinical Practice |date=October 2012 |volume=66 |issue=10 |pages=976–83 |doi=10.1111/j.1742-1241.2012.02986.x |pmid=22889110 |pmc=3469735}} 4. ^{{cite journal |last=Tefferi |first=A |title=Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. |journal=American Journal of Hematology |date=March 2011 |volume=86 |issue=3 |pages=292–301 |doi=10.1002/ajh.21946 |pmid=21351120}} 5. ^1 2 3 {{cite journal |last=Vannucchi |first=AM |title=Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia |journal=Internal and Emergency Medicine |date=June 2010 |volume=5 |issue=3 |pages=177–84 |doi=10.1007/s11739-009-0319-3 |pmid=19789961}} 6. ^{{cite journal |vauthors=Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR |title=Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 |journal=The New England Journal of Medicine |volume=369 |issue=25 |pages=2391–405 |date=Dec 2013 |pmid=24325359 |pmc=3966280 |doi=10.1056/NEJMoa1312542}} 7. ^{{cite journal |vauthors=Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R |title=Somatic mutations of calreticulin in myeloproliferative neoplasms |journal=The New England Journal of Medicine |volume=369 |issue=25 |pages=2379–90 |date=Dec 2013 |pmid=24325356 |doi=10.1056/NEJMoa1311347}} 8. ^{{cite journal |vauthors=Campbell PJ, Green AR |title=Management of polycythemia vera and essential thrombocythemia |journal=Hematology / The Education Program of the American Society of Hematology |volume= 2005|issue= |pages=201–8 |year=2005 |pmid=16304381 |doi=10.1182/asheducation-2005.1.201 |url=http://asheducationbook.hematologylibrary.org/content/2009/1/621.full.pdf}} 9. ^1 {{cite journal |last1=Vardiman |first1=JW |last2=Thiele |first2=J |last3=Arber |first3=DA |last4=Brunning |first4=RD |last5=Borowitz |first5=MJ |last6=Porwit |first6=A |last7=Harris |first7=NL |last8=Le Beau |first8=MM |last9=Hellström-Lindberg |first9=E |last10=Tefferi |first10=A |last11=Bloomfield |first11=CD |title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. |journal=Blood |date=July 2009 |volume=114 |issue=5 |pages=937–51 |doi=10.1182/blood-2009-03-209262 |pmid=19357394 |url=http://bloodjournal.hematologylibrary.org/content/114/5/937.full.pdf }} 10. ^1 2 3 4 5 {{cite journal |last=Cervantes |first=F |title=Management of essential thrombocythemia. |journal=Hematology / The Education Program of the American ĺSociety of Hematology |date=2011 |volume=2011 |pages=215–21 |doi=10.1182/asheducation-2011.1.215 |pmid=22160037 }} 11. ^1 2 3 {{cite journal |last=Birgegård |first=G |title=Pharmacological management of essential thrombocythemia. |journal=Expert Opinion on Pharmacotherapy |date=July 2013 |volume=14 |issue=10 |pages=1295–306 |doi=10.1517/14656566.2013.797408 |pmid=23668666}} 12. ^1 2 3 {{cite journal |last1=Tefferi |first1=A |last2=Barbui |first2=T |title=Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. |journal=Leukemia |date=August 2013 |volume=27 |issue=8 |pages=1617–20 |doi=10.1038/leu.2013.99 |pmid=23558521 |pmc=3740400}} 13. ^1 2 {{cite journal |last1=Fabris |first1=F |last2=Randi |first2=ML |title=Essential thrombocythemia: past and present.|journal=Internal and Emergency Medicine |date=October 2009 |volume=4 |issue=5 |pages=381–8 |doi=10.1007/s11739-009-0284-x |pmid=19636672}} 14. ^1 2 3 {{cite journal |last1=Valera |first1=MC |last2=Parant |first2=O |last3=Vayssiere |first3=C |last4=Arnal |first4=JF |last5=Payrastre |first5=B |title=Essential thrombocythemia and pregnancy |journal=European Journal of Obstetrics, Gynecology, and Reproductive Biology |date=October 2011 |volume=158 |issue=2 |pages=141–7 |doi=10.1016/j.ejogrb.2011.04.040 |pmid=21640467}} External links{{Medical resources| ICD10 = {{ICD10|D|75|2|d|70}}, {{ICD10|D|47|3|d|37}} | ICD9 = {{ICD9|238.71}} | ICDO = {{ICDO|9962|3}} | OMIM = 187950 | DiseasesDB = 4522 | MedlinePlus = 000543 | eMedicineSubj = med | eMedicineTopic = 2266 | MeshID = D013920 }}
2 : Myeloid neoplasia|Coagulopathies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。